0J2O logo

Halozyme Therapeutics LSE:0J2O Stock Report

Last Price

US$47.44

Market Cap

US$6.0b

7D

-0.4%

1Y

28.5%

Updated

26 Dec, 2024

Data

Company Financials +

Halozyme Therapeutics, Inc.

LSE:0J2O Stock Report

Market Cap: US$6.0b

0J2O Stock Overview

A biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. More details

0J2O fundamental analysis
Snowflake Score
Valuation6/6
Future Growth5/6
Past Performance5/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Halozyme Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Halozyme Therapeutics
Historical stock prices
Current Share PriceUS$47.44
52 Week HighUS$65.40
52 Week LowUS$33.22
Beta1.24
1 Month Change-1.25%
3 Month Change-17.04%
1 Year Change28.49%
3 Year Change18.31%
5 Year Changen/a
Change since IPO150.48%

Recent News & Updates

Recent updates

Shareholder Returns

0J2OGB BiotechsGB Market
7D-0.4%-1.9%-0.6%
1Y28.5%-25.0%2.7%

Return vs Industry: 0J2O exceeded the UK Biotechs industry which returned -25% over the past year.

Return vs Market: 0J2O exceeded the UK Market which returned 2.7% over the past year.

Price Volatility

Is 0J2O's price volatile compared to industry and market?
0J2O volatility
0J2O Average Weekly Movement8.8%
Biotechs Industry Average Movement7.0%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.5%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0J2O's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0J2O's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
1998373Helen Torleyhalozyme.com

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.

Halozyme Therapeutics, Inc. Fundamentals Summary

How do Halozyme Therapeutics's earnings and revenue compare to its market cap?
0J2O fundamental statistics
Market capUS$6.05b
Earnings (TTM)US$392.47m
Revenue (TTM)US$947.36m

15.4x

P/E Ratio

6.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0J2O income statement (TTM)
RevenueUS$947.36m
Cost of RevenueUS$249.60m
Gross ProfitUS$697.75m
Other ExpensesUS$305.29m
EarningsUS$392.47m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)3.08
Gross Margin73.65%
Net Profit Margin41.43%
Debt/Equity Ratio332.3%

How did 0J2O perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 14:52
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Halozyme Therapeutics, Inc. is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
James BirchenoughBarclays
Robert WassermanBenchmark Company